Targets › IL7
6 programs from 4 companies in 7 trials: 5 Phase 1, 2 Phase 2; Oncology, Infectious disease; next expected readout Nov 2026.
Hematopoietic cytokine that plays an essential role in the development, expansion, and survival of naive and memory T-cells and B-cells thereby regulating the number of mature lymphocytes and maintaining lymphoid homeostasis. Mechanistically, exerts its biological effects through a receptor composed of IL7RA subunit and the cytokine receptor common subunit gamma/CSF2RG. Binding to the receptor leads to activation of…. (UniProt, P13232)
Open in Phaseline: the race on IL7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mayo Clinic | Efineptakin alfa IL-7 hybrid Fc fusion protein; enhances T cell proliferation and survival | IL7 | Phase 2 | High Grade Astrocytic Tumor | Sep 2031 |
| National Cancer Institute (NCI) | CYT107 Recombinant glycosylated human interleukin-7 | IL7 | Phase 2 | Kaposi Sarcoma | Jan 2036 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Recombinant human interleukin (IL) 7-hyFc (NT-I7, Efineptakin Alfa) Recombinant human IL-7 fusion protein (IL-7-hyFc) | IL7 | Phase 1 | Idiopathic CD4 Lymphopenia | Nov 2026 |
| Washington University School of Medicine | Recombinant human interleukin-7 (CYT107) Interleukin-7 receptor agonist; promotes T cell reconstitution | IL7 | Phase 1 | Multiple Myeloma | Aug 2027 |
| Washington University School of Medicine | NT-I7 Recombinant human IL-7 (interleukin-7); promotes CAR-T cell expansion and efficacy | IL7 | Phase 1 | Large B-cell Lymphoma; Multiple Myeloma | Nov 2027 |
| Washington University School of Medicine | rhIL-7-hyFc Recombinant human IL-7 with hyper-stable Fc domain | IL7 | Phase 1 | Glioma | Apr 2028 |
Multiple Myeloma (2) Large B-cell Lymphoma (1) High Grade Astrocytic Tumor (1) Kaposi Sarcoma (1) Idiopathic CD4 Lymphopenia (1) Glioma (1)
protein or peptide (2), mixed (2), small molecule (2)
Washington University School of Medicine (3) Mayo Clinic (1) National Cancer Institute (NCI) (1) National Institute of Allergy and Infectious Diseases (NIAID) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.